US 8614183
Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2
granted A61KA61K38/179A61K38/1825
Quick answer
US patent 8614183 (Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2) held by Five Prime Therapeutics, Inc. expires Mon Dec 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Five Prime Therapeutics, Inc.
- Grant date
- Tue Dec 24 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 11
- CPC classes
- A61K, A61K38/179, A61K38/1825, A61P, A61P35/00